Evotec AG and the Jain Foundation have extended and expanded their research collaboration using Evotec's assay development and screening capabilities to support the Jain Foundation's research efforts to find a cure for dysferlinopathy. Financial details were not disclosed.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We look forward to our continued collaboration with the Jain Foundation on this project. This collaboration highlights both the increasing role that foundations play in delivering solutions for unmet medical needs and also how Evotec's broad and comprehensive discovery platform can be leveraged in support of these goals in a highly efficient and effective manner."
Dr. Plavi Mittal, president and chief executive officer of the Jain Foundation added, "We are excited to be moving toward screening compound libraries with Evotec. This is an important step toward accomplishing our mission of finding a therapy for Limb-girdle muscular dystrophy type 2B /Miyoshi Myopathy (LGMD2B/MM)."
Evotec, Jain Foundation Extend Research Pact
Published August 21, 2013
blog comments powered by Disqus